Company / PP&E (Net)
Cullinan Therapeutics, Inc. PP&E (Net) History
FY2020-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest PP&E (Net)
$683.0K
FY2024
5-year range
$77.0K / $1.2M
FY2020-FY2024
Trend
-30.9%
vs FY2023
Sector context
#162 of 193
Health Care
What the data says
Cullinan Therapeutics, Inc.'s pp&e (net) of $683,000 is lower than 84% of companies in the Health Care sector (FY2024). Declined from $1M to $683,000 over the past 2 years.
Based on SEC 10-K filings.
$683,000 in FY2024 with a 3-year CAGR of +107.0%.
Declined from $1M to $683,000 over the past 2 years.
Health Care sector context is included.
PP&E (Net) over time
Growth rates
- 3-Year CAGR
- +107.0%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 16% in Health CareTop 84% of 193This company $683.0K Sector average $777.6M
▼
-99.9% below sector average
Key checks
Key Insights
- 3-year CAGR of +107.0%, indicating consistent growth.
- In FY2024, pp&e (net) decreased 30.9% year-over-year.
- Ranks #162 out of 193 companies in the Health Care sector.
- Peak pp&e (net) was recorded in FY2022.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 7.33 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | PP&E (Net)Value | YoY GrowthYoY |
|---|---|---|
| FY2024 | $683.0K | -30.9% |
| FY2023 | $989.0K | -15.8% |
| FY2022 | $1.2M | +1424.7% |
| FY2021 | $77.0K | -40.8% |
| FY2020 | $130.0K | - |
As of FY2024 · SEC 10-K · Updated Jul 2, 2026